BIACNA TOPICAL

025% w/w, formulated as a topical gel. 025%) tretinoin in an aqueous based gel. Duration of treatment 12 weeks. Treatment beyond 12 weeks may call for evaluation by the physician.

Recommended Dose and Administration Adults, children 12 years of age and older:

At bedtime the entire face should be washed with mild soap and dried. A pea-sized amount of BIACNA should be squeezed onto one fingertip, dot onto the chin; cheeks, nose, and forehead, then gently rub over the entire face once daily.

BIACNA should be kept away from the eyes, the mouth, angles of the nose, and mucous membranes. BIACNA is not for oral, ophthalmic, or intravaginal use. Missed Dose In case of a missed dose of BIACNA the patient should wait for the next dose at the usual time.

Patients should not double the dose to make up for the forgotten dose. 025% w/w) is applied excessively, marked redness, peeling or discomfort can occur. If excess application occurs accidentally or through over-enthusiastic use, the face should be gently washed with a mild soap and warm water.

Topically applied clindamycin phosphate from BIACNA can be absorbed in sufficient amounts to cause systemic gastrointestinal side effects including abdominal pain, nausea, vomiting and diarrhea. In the case of overdosage BIACNA should be discontinued for several days before resuming therapy.

In the event of accidental ingestion, the same adverse reactions effects as those expected with oral tretinoin and clindamycin including teratogenesis in women and gastrointestinal side effects including abdominal pain, nausea, diarrhea, bloody diarrhea and colitis are expected.

) For management of a suspected drug overdose, please contact your regional Poison Control Centre. 025%, formulated as a topical gel. Clindamycin Clindamycin is a semisynthetic derivative of the parent compound lincomycin that is produced by Streptomyces lincolnensis and is predominantly bacteriostatic.

Clindamycin binds to the 50S ribosomal subunits of susceptible bacteria and prevents elongation of peptide chains by interfering with peptidyl transfer, thereby suppressing bacterial protein synthesis. Clindamycin has in vitro activity against Propionibacterium acnes, an organism which has been associated with acne vulgaris; however, the clinical significance of this activity against P.